Tirzepatide for women with early endometrial changes or cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 18 with obesity (BMI over 30).
- You have been diagnosed with endometrial intraepithelial neoplasia or a specific early type of endometrial cancer (grade 1).
- You are scheduled for a hysterectomy (surgery to remove the uterus).
- You have not taken any prescription or other medications meant to change your weight in the last 3 months.
- You do not have diabetes requiring insulin or a history of severe low blood sugar.
- You do not have certain stomach or pancreas conditions, such as pancreatitis or gastroparesis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests whether a weight-loss medication (tirzepatide) can help shrink early-stage, low-grade endometrial cancer or atypical hyperplasia while you keep your uterus for future pregnancy. It is designed for women who are overweight and wish to preserve their fertility.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.